ReviewEye (London, England)2017
Electronic retinal implants and artificial vision: journey and present.
Review in Eye (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 137 citations in OpenAlex.
- Bilateral retinal implants for improving visual restoration: a simulated bionic vision study.Medical & biological engineering & computing · 2026Article
- Next-generation smart ophthalmic biomaterials: From passive response to active interaction and closed-loop control.Bioactive materials · 2026Review
- Brain-Computer Interfaces for Vision Recovery in Precortical Vision Loss.Eye and brain · 2026Review
- Differential modulation of movement speed with state-dependent deep brain stimulation in Parkinson's disease.Science advances · 2025Article
- Gustatory interface for operative assessment and taste decoding in patients with tongue cancer.Nature communications · 2024Article
- Assessment of visual function in blind mice and monkeys with subretinally implanted nanowire arrays as artificial photoreceptors.Nature biomedical engineering · 2024Article
- Emerging Medical Technologies and Their Use in Bionic Repair and Human Augmentation.Bioengineering (Basel, Switzerland) · 2024Review
- PRPF31-retinitis pigmentosa: Challenges and opportunities for clinical translation.Vision research · 2023Review
- Smart Contact Lenses as Wearable Ophthalmic Devices for Disease Monitoring and Health Management.Chemical reviews · 2023Review
- Article
- Strategies for management of retinal degenerative disorders.Indian journal of ophthalmology · 2023Article
- In Vivo Penetrating Microelectrodes for Brain Electrophysiology.Sensors (Basel, Switzerland) · 2022Review
- Optogenetic approaches to therapy for inherited retinal degenerations.The Journal of physiology · 2022Review
- Implications of Neural Plasticity in Retinal Prosthesis.Investigative ophthalmology & visual science · 2022Article
- The medical cyborg concept.EMBnet.journal · 2022Article
- Engineering strategies towards overcoming bleeding and glial scar formation around neural probes.Cell and tissue research · 2022Review
- Progress of clinical therapies for dry age-related macular degeneration.International journal of ophthalmology · 2022Review
- Learning to see again: Perceptual learning of simulated abnormal on- off-cell population responses in sighted individuals.Journal of vision · 2021Article
- Neuromodulation using electroosmosis.Journal of neural engineering · 2021Article
- Simultaneous Power Feedback and Maximum Efficiency Point Tracking for Miniaturized RF Wireless Power Transfer Systems.Sensors (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinitis pigmentosa and age-related macular degeneration are two significant causes of severe visual dysfunction. In both, the retinal photoreceptors degenerate, preventing successful conversion of light into electrical energy that is interpreted in the visual cortex as visual function. Artificial vision or visual function began over two centuries ago with the idea of creating artificial light pulses, or phosphenes, through cortical stimulation. The pursuit is now on to improve artificial visual function. Two retinal implants appear the most likely to succeed in the future having undergone multicentre human trials: the Argus II electronic epiretinal device (Second Sight Medical Products, CA, USA) and Alpha-IMS electronic subretinal device (Retina Implant AG, Germany). The trial results to date are encouraging with visual improvement and acceptable safety profiles reported for both devices. At present, the visual function generated by either device does not offer high enough resolution or acuity for a patient to regain a fully functional life. Despite this, both devices not only have the potential, but have actually improved the vision-related quality of life in a significant number of patients implanted. With this in mind, the economic argument is clear. Provided device-life is long enough, its cost should be acceptable for the obtained improvement in the quality of life. The aim of this Review Article is to assist those readers that may be considering offering any of these devices as a treatment for blindness in Retinitis Pigmentosa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.